| Literature DB >> 14505493 |
David C Warhurst1, John C Craig, Ipemida S Adagu, David J Meyer, Sylvia Y Lee.
Abstract
BACKGROUND: The 8-amino and 9-hydroxy substituents of antimalarial cinchona alkaloids have the erythro orientation while their inactive 9-epimers are threo. From the X-ray structures a 90 degrees difference in torsion angle between the N1-H1 and C9-O12 bonds in the two series is believed to be important. In order to kill the malaria parasite, alkaloids must cross the erythrocyte and parasite membranes to accumulate in the acid digestive vacuole where they prevent detoxication of haematin produced during haemoglobin breakdown.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14505493 PMCID: PMC201021 DOI: 10.1186/1475-2875-2-26
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Figure 1Cinchona alkaloids: structures to illustrate the stereochemistry. Q = quinine, QD = quinidine, EQ = epiquinine, EQD = epiquinidine, HQ = hydroquinine, HQD = hydroquinidine, CD = cinchonidine, C = cinchonine, ECD = epicinchonidine, EC = epicinchonine.
Physicochemical parameters of Cinchona alkaloids. cpd. = compound, VAR = calculated vacuolar accumulation ratio. S = chloroquine-sensitive, R = chloroquine-resistant. S/R = ratio of IC50 values. BHIA = % inhibition in β-haematin inhibition test
| Cpd. | pKa1 | pKa2 | Log P | Log D (pH7.4) | Log D (pH5.2) | VAR | IC50 nM S | IC50 nM R | RATIO S/R | BHIA % inhib. |
| Q | 8.58a | 4.12b | 3.17c | 1.97e | 0.30 | 161.0 | 29.315 | 103.215 | 0.28 | 84 ± 1 |
| 2.79d | 1.96f | -0.25f | ||||||||
| QD | 8.58g | 4.42h | 2.84i | 1.66j | 0.40k | 173.2 | 13.415 | 43.715 | 0.31 | 85 ± 9 |
| 2.79d | 1.63f | -0.61f | ||||||||
| HQ | 9.01 l | 4.29 | 3.07 | 1.50 | 0.53 | 173.6 | 21.315 | 151.715 | 0.14 | 93 ± 0.6 |
| 3.27d | 1.45f | -0.79f | ||||||||
| HQD | 9.16 | 4.34 | 3.43 | 1.72 | 0.75 | 177.5 | 10.415 | 74.115 | 0.14 | 95 ± 0.4 |
| 3.27d | 1.66f | -0.59f | ||||||||
| C | 8.35m | 4.28n | 2.82o | 1.85p | -0.38f | 159.6 | 18.346 | 70.846 | 0.26 | 94 ± 0.5 |
| 2.49d | 1.82f | |||||||||
| CD | 8.40q | 4.17r | 2.68s | 1.73t | -0.56f | 157.5 | 69.546 | 206.846 | 0.34 | 94 ± 0.4 |
| 2.49d | 1.64f | |||||||||
| EQ | 9.54u | 4.08 | 2.90 | 0.76 | -1.44 | 169.2 | 347115 | 117915 | 2.94 | 2 ± 13 |
| 2.79d | 0.76f | -1.47f | ||||||||
| EQD | 9.39v | 4.15 | 2.53 | 0.55 | -1.2 | 170.8 | 270015 | 102415 | 2.64 | 12 ± 12 |
| 2.79d | 0.54f | -1.70f | ||||||||
| CQ | 10.18 | 8.38 | 4.72 | 0.96 | -3.44 | 22750 | 18.5 | 264 | 0.07 | 81 ± 15 |
| 0.92f | -3.44f | |||||||||
| VE | 8.462 | <0 | 3.7962 | 2.75f | 0.59f | 144.2 | 720053 | 250053 | 2.88 | 0 ± 21 |
| PMZ | 9.1142 | <0 | 4.7542 | 3.03f | 0.84f | 155.5 | 143652 | 83552 | 1.70 | 15 ± 22.5 |
a: Lit 8.43[64], 8.4[39], 8.05[65], 8.59[66]. In 80% methylcellosolve/20% water 7.73[41], 7.25[67] ; b: Lit. 4.34[64],4.32 [39], 4.33 [66]. In 80% methylcellosolve 2.81[67], 2.38[68] ; c: Lit. 3.44[22], 2.64[65] ; d: Calc. from CLogP ; e: Lit. 1.90[65], 2.14[22], 2.54[69], 1.73(pH7.0)[70] ; f: Calc from eqn. (1). ; g: Lit. 8.79[64], 7.95[41], 8.78[42]. In 80% methylcellosolve 7.95[41]7.36[67] ; h: Lit. 4.34[64], in 80% methylcellosolve 2.66[67], 2.40[68] ; i: Lit: 2.88[65], 3.71[42] ; j: Lit. 2.03[72], 2.07[74],2.11[31], 2.22[65]; k: Lit: -0.07[42] ; l: Lit. 8.87[40] ; m: Lit. 8.35[40], 8.32[65]. In 80% methylcellosolve 7.36[68] ; n: Lit. 4.28[67], In 80% methylcellosolve 2.80[67], 2.15[68] ; o: Lit 2.82[65]; p: Lit 1.85[65] ; q: Lit. 8.40[40], 8.30[65]; r: Lit. 4.17[40]. In 80% methylcellosolve 2.66[67], 2.12[68] ; s: Lit. 2.68[65] ; t: Lit. 1.73[65] ; u: Lit. In 80% methylcellosolve 8.44[41] ; v: Lit. in 80% methylcellosolve 8.32[41].
Figure 2% β-haematin synthesis inhibition (BHIA) by cinchona alkaloids, chloroquine (CQ), verapamil (VE), promethazine (PMZ) and water (Cont). Standard deviations are shown (n = 9).
Electronic and structural parameters of cinchona alkaloids in aqueous solvent, based on the common pharmacophores described for (-) mefloquine and quinine and (+) mefloquine and quinidine by Karle & Karle [17]. (*dipole moment calculated for free base).
| drug in water | MM+ energy <0.004 | dipole moment* | proton affinity | O12-N1 | N1-C5' | ring-O12 torsion° | O12-N1 torsion° | H8-C8-C9-H9 dihedral° | H-N1-C9-O12 torsion° |
| Kcal/mole | Debye | Kcal/mole | Å | Å | |||||
| Q | 11.9 | 1.88 | 208.85 | 3.14 | 4.1 | 157.8 | -83.8 | -82.6 | -123.2 |
| EQ | 15.5 | 2.44 | 213.36 | 2.77 | 4.7 | 40.6 | 43.3 | 174.0 | -5.9 |
| QD | 18.9 | 1.66 | 208.61 | 3.09 | 4.2 | -161.1 | 78.2 | 74.7 | 104.4 |
| EQD | 12.8 | 2.21 | 213.84 | 2.82 | 4.7 | -43.2 | -49.1 | -175.8 | 0.6 |
| CD | 11.1 | 1.15 | 209.38 | 3.21 | 4.2 | 144.9 | -91.0 | -86.8 | -129.6 |
| ECD | 13.6 | 1.54 | 213.88 | 2.79 | 4.6 | 45.1 | 46.0 | 175.0 | -5.9 |
| C | 10.9 | 0.96 | 209.78 | 3.19 | 4.1 | -156.0 | 88.9 | 85.3 | 118.3 |
| EC | 13.5 | 1.27 | 213.75 | 2.85 | 4.7 | -45.4 | -50.2 | -176.2 | -2.5 |
| HQ | 10.4 | 2.08 | 209.39 | 3.20 | 4.1 | 156.1 | -83.6 | -82.8 | -123.6 |
| HQD | 10.7 | 1.79 | 209.75 | 3.23 | 4.2 | -152.7 | 89.5 | 88.8 | 118.6 |
Figure 3Space-filling models of cinchona alkaloids optimised in solvent water. Each structure is orientated facing a putative receptor. N = dark blue, C = light blue, O = red, H = grey.
1:1 Quinine-haematin complex: Observed and calculated values of electronic absorption peaks and peak strengths. (* Peak strength normalised by taking γ peak strength as 1.0.)
| α peak (nm) | β peak (nm) | γ peak (nm) | α peak * strength | β peak* strength | γ peak* strength | [Q] / [H] | |
| observed | 602 | 490 | 408 | 10 | 1.2 | 1 | 0.8 |
| calculated | 545.4 | 489.4 | 408.4 | 5.4 | 1.1 | 1 | 1 |
| Ratio obs/calc | 1.1 | 1.0 | 1.0 | 1.9 | 1.1 | 1 | 0.8 |
Figure 4Views of Q-haematin and EQ-haematin models from the edge of the porphyrin ring to show comparative orientation (black arrows) of the electric field of the alkaloid N-1 proton (H-1). The haematin iron atom (just visible) is coloured magenta.
Figure 5LogD values at pH 7.4 and activity in CQ-resistance (log [IC50S/IC50R]) for 4-aminoquinolines and cinchona alkaloids. 4-aminoquinoline values from ref. [73].